We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+31.98%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$148M
AUM Growth
–
Cap. Flow
+$140M
Cap. Flow %
95.07%
Top 10 Hldgs %
69.36%
Holding
30
New
29
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$19.4M
2
TARO
Taro Pharmaceutical Industries Ltd.
TARO
+$12.3M
3
PTX
Pernix Therapeutics Holdings, Inc.
PTX
+$10.8M
4
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$8.86M
5
AGEN
Agenus
AGEN
+$8.27M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 81.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
$23.5M 15.92%
+2,824,185
New +$19.4M
TARO
2
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$12.4M 8.41%
+83,800
New +$12.3M
RCPT
3
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$10.7M 7.26%
+87,500
New +$8.86M
PTX
4
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$10.7M 7.22%
+113,458
New +$10.8M
AGEN
5
Agenus
AGEN
$280M
$10.5M 7.1%
+134,410
New +$8.27M
SRNE
6
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$9.16M 6.21%
+910,100
New +$4.61M
EBS icon
7
Emergent Biosolutions
EBS
$374M
$9M 6.1%
+330,635
New +$7.88M
MGNX icon
8
MacroGenics
MGNX
$235M
$5.7M 3.86%
+162,500
New +$4.05M
CASC
9
DELISTED
Cascadian Therapeutics, Inc.
CASC
$5.68M 3.85%
+498,606
New +$5.41M
BLCM
10
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$5.07M 3.43%
+22,000
New +$4.72M
LJPC
11
DELISTED
La Jolla Pharmaceutical Company
LJPC
$4.55M 3.08%
+246,499
New +$2.93M
TLGT
12
DELISTED
Teligent, Inc
TLGT
$4.07M 2.76%
+46,234
New +$4.33M
CELG
13
CALL
DELISTED
Celgene Corp
CELG
$3.92M 2.66%
+150,000
New +$15.8M
ARWR icon
14
Arrowhead Research
ARWR
$11.9B
$3.88M 2.63%
+525,000
New +$3.57M
AVDL
15
DELISTED
Avadel Pharmaceuticals
AVDL
$3.68M 2.49%
+214,805
New +$3.07M
RXDX
16
DELISTED
Ignyta, Inc.
RXDX
$3.57M 2.42%
+521,233
New +$3.54M
ALIM
17
DELISTED
Alimera Sciences
ALIM
$3.39M 2.3%
+44,973
New +$3.65M
DVAX
18
DELISTED
Dynavax Technologies
DVAX
$3.36M 2.28%
+199,332
New +$3.04M
VCEL icon
19
Vericel Corp
VCEL
$2.34B
$3.22M 2.18%
+1,058,820
New +$3.01M
BIOL
20
DELISTED
Biolase, Inc.
BIOL
$2.06M 1.4%
+63
New +$1.97M
NVAX icon
21
Novavax
NVAX
$1.21B
$1.78M 1.21%
+15,000
New +$1.57M
CPRX
22
DELISTED
Catalyst Pharmaceutical
CPRX
$1.64M 1.11%
+550,670
New +$1.51M
INNL
23
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$1.33M 0.9%
+225,000
New +$1.57M
FWP
24
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$1.04M 0.71%
+7,143
New +$1.03M
HRTX icon
25
Heron Therapeutics
HRTX
$92.4M
$663K 0.45%
+65,900
New +$538K
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q4 2014 Portfolio in Review

Q4 2014 is the first quarter with a 13F filing on record for Avoro Capital Advisors, which disclosed 30 positions worth $148M. Its ten largest holdings account for 69% of the portfolio.

Its largest position is Amicus Therapeutics: 2,824,185 shares worth $23.5M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets.

  • Avoro Capital Advisors's largest Q4 2014 buy was Amicus Therapeutics: 2,824,185 shares worth $23.5M.
  • Avoro Capital Advisors's ten largest holdings make up 69% of its $148M portfolio in Q4 2014.
  • Avoro Capital Advisors disclosed 30 positions in Q4 2014, its first 13F filing on record.

Based on Avoro Capital Advisors's 13F filing for Q4 2014, filed 13 Feb 2015.